Chair: Tadeusz Robak, MD, PhD – Department of Hematology, Medical University of Lodz; Department of General Hematology and Internal Medicine, Copernicus Memorial Hospital
Speaker: Iwona Hus, MD, PhD – National Medical Institute of the Ministry of the Interior and Administration
08:15 - 08:25 CEST
Welcome and Introductions
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Chair: Tadeusz Robak, MD, PhD – Department of Hematology, Medical University of Lodz; Department of General Hematology and Internal Medicine, Copernicus Memorial Hospital
Speaker: Iwona Hus, MD, PhD – National Medical Institute of the Ministry of the Interior and Administration
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Speaker: Frederik Damm, MD – Dept of Hematology, Oncology, & Cancer Immunology, Charité - Universitätsmedizin Berlin
09:25 - 09:40 CEST
Panel Discussion with Interactivity and Audience Q&A
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
09:40 - 09:50 CEST
(1022) Unravelling the Clinical and Biological Features of Accelerated Chronic Lymphocytic Leukemia
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Primary Author / Presenter: Francesco Angotzi, MD – Hematology Unit, University of Padova
09:50 - 10:00 CEST
(1024) ROR1-Signaling Enhances Survival and Drug-Resistance of del(17p)/TP53-Mutated CLL by Mitigating Oxidative Stress Via Activation of NRF2
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Primary Author / Presenter: Emanuela M. Ghia, PhD – Center for Novel Therapeutics; University of California, San Diego
Oral
10:00 - 10:10 CEST
(1023) Clinical and Biological Impact of MYC Overexpression in Chronic Lymphocytic Leukemia With and Without TP53 Disruption
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Primary Author / Presenter: Alba Garrote de Barros, MSc – Department of Translational Hematology, Instituto de Investigación Hospital 12 de Octubre (imas12), Hematological Malignancies Clinical Research Unit H12O-CNIO, CIBERONC, ES 28041
10:10 - 10:15 CEST
(1001) IgM Monoclonal Gammopathy Arises Directly From MBL/CLL Cells: Evidence From Proteomic Analyses
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Primary Author: Uday Aditya Sarkar, PhD – Dana-Farber Cancer Institute, Harvard Medical School
Co-Author / Presenter: Paolo Ghia, MD, PhD – Università Vita Salute and IRCCS Ospedale San Raffaele
10:15 - 10:35 CEST
Morning Break
10:15 - 10:35 CEST
Morning Break
Location: ICE, Foyer 1, Level 1
10:35 - 12:20 CEST
Session 2: Genomics, Epigenetics, and Proteomics of CLL
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Speaker: Ferran Nadeu, PhD – Institut d'Investigacions Biomèdiques August Pi i Sunyer
10:50 - 11:05 CEST
Epigenetics
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Speaker: Inaki Martin-Subero, PhD – Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
11:05 - 11:20 CEST
Proteomics
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Speaker: Fabienne Meier-Abt, MD, PhD – Institute of Medical Genetics, University of Zurich; Department of Medical Oncology and Hematology, University Hospital Zurich
11:20 - 11:35 CEST
Proteomics Changes During Ibrutinib Therapy
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Panel Discussion with Interactivity and Audience Q&A
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
11:50 - 12:00 CEST
(1121) High-Risk Molecular Features Eclipse Genomic Complexity in Predicting CLL Patient Outcomes; Insights From the UK CLL4, ARCTIC, and ADMIRE Trials
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Primary Author / Presenter: Helen Parker, PhD – University of Southampton
12:00 - 12:10 CEST
(1122) Integrative Epi(genome) Analysis of CD49d Bbimodal Expression Reveals Epigenetically Driven Phenotypic Transitions in CLL
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Primary Author / Presenter: Federico Pozzo, PhD – Centro di Riferimento Oncologico di Aviano
12:10 - 12:15 CEST
(1102) Unravelling Prognostic Significance: Long-Read Nanopore Sequencing of TP53 and IGHV in Chronic Lymphocytic Leukaemia Patients in Tanzania
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Beyond Adhesion: Integrin Crosstalk With the BCR in CLL
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Speaker: Tanja Nicole Hartmann, Prof., Dr. – Medical Center University Freiburg, Head Research and Clinical Research Coordination, Comprehensive Cancer Center Freiburg
14:15 - 14:35 CEST
Understanding the Role and Targeting the Non-Lymphoid Elements in the Tumor Microenvironment
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Speaker: Alan G. Ramsay, PhD – Lymphoma Immunology Group, Kings College London
14:35 - 14:55 CEST
Extracellular Vesicles in CLL
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Primary Author / Presenter: Miroslav Boudny, PhD – Dept of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Rep.; CEITEC, Masaryk University
15:15 - 15:20 CEST
(1209) Early Effects of Venetoclax Monotherapy on Immune Cells in Patients With Chronic Lymphocytic Leukemia
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Primary Author / Presenter: Olina Lind, MSc – Department of Oncology-Pathology, Karolinska Institutet
15:20 - 15:40 CEST
Afternoon Break
15:20 - 15:40 CEST
Afternoon Break
Location: ICE, Foyer 1, Level 1
15:40 - 17:10 CEST
Session 4: Preclinical Studies of Novel Therapies
Co-Chair: Paolo Ghia, MD, PhD – Università Vita Salute and IRCCS Ospedale San Raffaele
Co-Chair: Shih-Shih Chen, PhD – The Feinstein Institutes for Medical Research
15:40 - 17:10 CEST
Session 4: Preclinical Studies of Novel Therapies
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Co-Chair: Paolo Ghia, MD, PhD – Università Vita Salute and IRCCS Ospedale San Raffaele
Co-Chair: Shih-Shih Chen, PhD – The Feinstein Institutes for Medical Research
15:40 - 15:55 CEST
Exploring Siglec-6 as a Novel Target for Potential Therapeutic Utility in Chronic Lymphocytic Leukemia
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Lessons From Solid Tumors for CLL: Harnessing B Cells Inside and Outside of Tertiary Lymphoid Structures for New Therapeutics
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Speaker: Tullia Bruno, PhD – The University of Pittsburgh Hillman Cancer Center
16:25 - 16:35 CEST
(1311) Targeted Degradation of NF-κB RelA/p65 by PBD-Based PROTACs as a Novel Therapeutic Strategy in Chronic Lymphocytic Leukaemia
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Primary Author / Presenter: Chris Pepper, PhD – Brighton and Sussex Medical School
16:35 - 16:45 CEST
(1312) Zelebrudomide (NX-2127) Is a Cereblon-Modulating BTK Degrader That Reverses Immune Dysfunction and Modifies Both T-cell and CLL-Cell Transcriptional Signatures in Patients With CLL
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Primary Author / Presenter: Tiana Huynh, MS – City of Hope - Irell and Manella Graduate School of Biological Sciences
16:45 - 16:50 CEST
(1305) CLECL1⁺ Proliferative CLL Cells Remodel the Lymph Node Microenvironment Through Fibroblast Reprogramming, Th2 Polarization, and M2 Macrophage Induction to Promote Immune Evasion and Disease Progression
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Primary Author / Presenter: Shih-Shih Chen, PhD – The Feinstein Institutes for Medical Research
16:50 - 16:55 CEST
(1303) Targeting Lysosomes in the Chronic Lymphocytic Leukemia Microenvironment
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1